Edition:
United States

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

2.45USD
17 Aug 2018
Change (% chg)

$-0.38 (-13.27%)
Prev Close
$2.83
Open
$2.85
Day's High
$2.85
Day's Low
$2.38
Volume
717,188
Avg. Vol
110,217
52-wk High
$5.80
52-wk Low
$2.35

Chart for

About

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's... (more)

Overall

Beta: 0.28
Market Cap(Mil.): $115.86
Shares Outstanding(Mil.): 47.29
Dividend: --
Yield (%): --

Financials

  ADMP.OQ Industry Sector
P/E (TTM): -- 28.29 30.45
EPS (TTM): -0.69 -- --
ROI: -69.14 12.92 12.63
ROE: -76.71 14.94 14.82

BRIEF-Adamis Pharmaceuticals Says Unless Earlier Terminated, Deal With Sandoz Will Expire 10 Yrs From Launch Of Product

* ADAMIS PHARMACEUTICALS - DEAL WITH SANDOZ FOR SYMJEPI PROVIDES SANDOZ WILL PAY TO CO 50% OF NET PROFIT FROM NET SALES OF PRODUCT

Jul 02 2018

BRIEF-Adamis Pharmaceuticals Updates Symjepi Commercialization Plans

* ADAMIS PHARMACEUTICALS UPDATES SYMJEPI COMMERCIALIZATION PLANS

Feb 23 2018

Competitors

  Price Chg
GlaxoSmithKline plc (GSK.L) 1,617.00 +7.00

Earnings vs. Estimates